Projects & Grants
| Monitoring Pharmacokinetics of Biopharmaceuticals in Patients with Inflammatory Bowel Disease and Its Impact on PharmacoEconomics | |
|---|---|
| Project Id | SGS02/LF/2018-2019 |
| Main solver | MUDr. Pavel Svoboda, Ph.D. |
| Period | 1/2018 - 12/2019 |
| Provider | Specifický VŠ výzkum |
| State | finished |
| Anotation | The project focuses on biological therapy of inflammatory bowel disease (IBD) and its pharmacoeconomics. The study aims to monitor the pharmacokinetics of the levels of biopharmaceuticals (infliximab and adalimumab) and of antibodies against them. Biological therapy represents an important progress in the treatment of IBD. Biological therapy is highly effective and substantially improves the patient?s condition within a short period of time. The therapy is, however, very expensive, could be accompanied with undesirable side effects, and with a risk of secondary failure resulting in a relapse of the disease. Factors determining the effectiveness of biological therapy include a sufficient level of biopharmaceuticals and production of antibodies against them, which can cause hypersensitivity. Monitoring the serum levels of biopharmaceuticals and antibodies against them could become an important ancillary examination in the course of biological therapy. The low levels of biopharmaceuticals may require adjustments of dosage to improve the therapeutic response; the high levels of biopharmaceuticals call for a reduction of dosage to increase safety in therapy, along with its cost-effectiveness. Serum antibodies against a biopharmaceutical can be considered as a reason for another type of biologic to be applied instead of mere adjustments in dosage. In contemporary clinical practice adjustments of dosage of biologics are based on empirical evidence, particularly on the therapeutic response, which may prove misleading both in clinical and economical senses. |
